Skip to main content
Caplight Logo









Cytospire Therapeutics

Cytospire Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.cytospire.com/

Last Round

Series A

May 5, 2026

Total Funding Raised

$83M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Cytospire Therapeutics is a biotechnology company developing a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

gamma delta T cell engagerspan-gamma delta T cell engagersimmuno-oncologyIOT cell engagerssolid tumor therapybispecific antibodiesgamma delta T cell therapygd T cell therapymultispecific antibodiesantibody engineeringimmune cell engagersEGFR targeted therapydrug discovery platformpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytospire Therapeutics Comparables

Compare Cytospire Therapeutics with similar companies based on industry and business-model similarity.

Cytospire Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Janux Therapeutics
77%
Ipsen
76%
Lava Therapeutics
75%

Cytospire Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 5, 2026

Key People

Founding team and executive leadership

Natalie Mount

Chief Executive Officer

Executive Team

Cytospire Therapeutics Investors

Notable investors and investment history

Cytospire Therapeutics investors
InvestorRounds
Servier VenturesSeries A
Medical Incubator JapanSeries A
British Business BankSeries A
4BIO CapitalSeed, Series A
AbingworthSeries A, Seed
Pathway BioventuresSeries A
LifeArc VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Grew 47% QoQ, from 19 to 28 employees.

  • May 27, 2026

    Grew 17% QoQ, from 18 to 21 employees.

Cytospire Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cytospire Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cytospire Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range28
Year Founded2023
Last FundingMay 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?